A detailed history of New England Research & Management, Inc. transactions in United Therapeutics Corp stock. As of the latest transaction made, New England Research & Management, Inc. holds 7,720 shares of UTHR stock, worth $2.88 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares
7,720
Previous 8,195 5.8%
Holding current value
$2.88 Million
Previous $2.61 Million 5.94%
% of portfolio
1.3%
Previous 1.25%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$311.04 - $363.55 $147,744 - $172,686
-475 Reduced 5.8%
7,720 $2.77 Million
Q2 2024

Jul 09, 2024

SELL
$228.26 - $319.04 $510,161 - $713,054
-2,235 Reduced 21.43%
8,195 $2.61 Million
Q1 2024

Apr 16, 2024

BUY
$210.76 - $249.51 $504,770 - $597,576
2,395 Added 29.81%
10,430 $2.4 Million
Q4 2023

Feb 06, 2024

SELL
$214.88 - $256.94 $100,993 - $120,761
-470 Reduced 5.53%
8,035 $1.77 Million
Q3 2023

Oct 10, 2023

BUY
$211.82 - $248.24 $471,299 - $552,334
2,225 Added 35.43%
8,505 $1.92 Million
Q2 2023

Jul 05, 2023

BUY
$205.19 - $232.99 $146,710 - $166,587
715 Added 12.85%
6,280 $1.39 Million
Q1 2023

Apr 06, 2023

BUY
$212.99 - $276.17 $237,483 - $307,929
1,115 Added 25.06%
5,565 $1.25 Million
Q4 2022

Jan 09, 2023

SELL
$205.95 - $280.43 $226,545 - $308,473
-1,100 Reduced 19.82%
4,450 $1.24 Million
Q3 2022

Oct 06, 2022

BUY
$203.3 - $244.17 $1.13 Million - $1.36 Million
5,550 New
5,550 $1.16 Million
Q1 2022

Apr 20, 2022

SELL
$166.16 - $213.96 $776,798 - $1 Million
-4,675 Closed
0 $0
Q4 2021

Jan 05, 2022

SELL
$184.32 - $216.08 $142,848 - $167,462
-775 Reduced 14.22%
4,675 $1.01 Million
Q3 2021

Oct 08, 2021

BUY
$179.86 - $214.88 $777,894 - $929,356
4,325 Added 384.44%
5,450 $1.01 Million
Q2 2021

Jul 15, 2021

SELL
$170.47 - $211.93 $362,248 - $450,351
-2,125 Reduced 65.38%
1,125 $202,000
Q1 2021

Apr 16, 2021

BUY
$153.94 - $174.85 $500,305 - $568,262
3,250 New
3,250 $544,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $17B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track New England Research & Management, Inc. Portfolio

Follow New England Research & Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New England Research & Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on New England Research & Management, Inc. with notifications on news.